Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s79, 2022. DOI: 10.25251/skin.6.supp.79. Disponível em: https://skin.dermsquared.com/skin/article/view/1837. Acesso em: 16 apr. 2025.